You are here

Article Text

Article menu
Sleep disordered breathing
Objective measurement of compliance during oral appliance therapy for sleep-disordered breathing
  1. Olivier M Vanderveken1,5,6,
  2. Marijke Dieltjens2,6,
  3. Kristien Wouters3,
  4. Wilfried A De Backer4,5,6,
  5. Paul H Van de Heyning1,5,6,
  6. Marc J Braem2,6
  1. 1Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Antwerp, Belgium
  2. 2Department of Special Care Dentistry, Antwerp University Hospital, Antwerp, Belgium
  3. 3Department of Scientific Coordination and Biostatistics, Antwerp University Hospital, Antwerp, Belgium
  4. 4Department of Pneumology, Antwerp University Hospital, Edegem, Antwerp, Belgium
  5. 5Multidisciplinary Sleep Disorders Unit, Antwerp University Hospital, Edegem, Antwerp, Belgium
  6. 6Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
  1. Correspondence to Professor Dr Olivier M Vanderveken, Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Wilrijkstraat 10, Edegem B-2650, Antwerp, Belgium; olivier.vanderveken{at}uza.be

Abstract

Background Oral appliance (OA) therapy is increasingly prescribed as a non-continuous positive airway pressure treatment modality for sleep-disordered breathing (SDB). Although OA therapy is reported to be efficacious for the treatment of SDB, data on compliance remain limited to self-report.

Methods In this 3-month prospective clinical trial, the main outcome was to assess the safety and feasibility of an objective measurement of compliance during OA therapy using an embedded microsensor thermometer with on-chip integrated readout electronics in 51 consecutive patients with an established diagnosis of SDB (AHI 18.0±11.9/h; age 47±10 y; BMI 26.6±4.0 kg/m2; men/women: 31/20). Patients were unaware of the purpose of the study.

Results No microsensor-related adverse events were recorded. In addition, no problems were encountered during the readout of the compliance data. Out of 51 microsensors, one had a technical defect and was lost to follow-up. In this study, the overall objective mean rate of OA use was 6.6±1.3 h per day with a regular OA users’ rate of 82% at the 3-month follow-up. Statistical analysis revealed no significant differences between objective and self-reported OA compliance data in this study.

Measurement of the objective OA compliance allowed us to calculate the mean disease alleviation (MDA) as the product of objective compliance and therapeutic efficacy. MDA serves as a measure of the overall therapeutic effectiveness, and turned out to be 51.1%.

Conclusions The results illustrate the safety and feasibility of objective measurement of OA compliance. The objective measurement of OA compliance allows for calculation of the MDA.

  • Sleep apnoea

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

https://doi.org/10.1136/thoraxjnl-2012-201900

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

      Files in this Data Supplement: